BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
51.47
+0.26 (0.51%)
At close: Sep 15, 2025, 4:00 PM EDT
51.45
-0.02 (-0.04%)
After-hours: Sep 15, 2025, 6:29 PM EDT
BridgeBio Pharma Market Cap
BridgeBio Pharma has a market cap or net worth of $9.84 billion as of September 15, 2025. Its market cap has increased by 109.48% in one year.
Market Cap
9.84B
Enterprise Value
10.88B
1-Year Change
109.48%
Ranking
Category
Stock Price
$51.47
Market Cap Chart
Since June 27, 2019, BridgeBio Pharma's market cap has increased from $3.32B to $9.84B, an increase of 196.39%. That is a compound annual growth rate of 19.10%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Sep 12, 2025 | 9.79B | 88.78% |
| Dec 31, 2024 | 5.19B | -26.16% |
| Dec 29, 2023 | 7.02B | 516.56% |
| Dec 30, 2022 | 1.14B | -53.61% |
| Dec 31, 2021 | 2.46B | -71.83% |
| Dec 31, 2020 | 8.72B | 101.23% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 27, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 678.14B |
| Johnson & Johnson | 428.83B |
| AbbVie | 385.71B |
| UnitedHealth Group | 319.26B |
| AstraZeneca | 247.84B |
| Novo Nordisk | 242.99B |
| Novartis AG | 240.09B |
| Abbott Laboratories | 232.75B |